Related Experiment Video
Updated: May 21, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
ELK3 promotes cisplatin resistance in ovarian cancer via regulating CHD4 gene expression
Qihua Peng1, Kaho Leung1, Yixuan Sun1
1Shanghai Sixth People's Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background:
Cisplatin resistance remains a major obstacle in the treatment of ovarian cancer (OC). Although ELK3, an ETS transcription factor, has been implicated in chemoresistance across various cancers, its specific role and molecular mechanisms in OC progression and cisplatin resistance remain poorly understood.
Methods:
ELK3 expression was analyzed in cisplatin-resistant OC cells using qPCR and Western blotting. Functional assays, including CCK-8, apoptosis analysis, and xenograft models, were employed to assess the impact of ELK3. Mechanistic insights were gained through Co-IP and histone lactylation analysis.
Results:
ELK3 was significantly upregulated in cisplatin-resistant OC tissues and cells, and its elevated expression correlated with poor patient survival according to TCGA and KM Plotter data. Knockdown of ELK3 sensitized OC cells to cisplatin by suppressing CHD4 expression and reducing histone lactylation levels. Importantly, restoration of CHD4 expression rescued cisplatin resistance in ELK3-deficient cells.
Conclusion:
The ELK3-CHD4-histone lactylation axis plays a critical role in driving cisplatin resistance in OC, highlighting its potential as a novel therapeutic target for overcoming chemoresistance.
Insights
ELK3 upregulation drives cisplatin resistance in ovarian cancer (OC) by affecting CHD4 and histone lactylation. Targeting the ELK3-CHD4 pathway may overcome chemoresistance in OC patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Cisplatin resistance is a significant challenge in ovarian cancer (OC) treatment.
- The role of ELK3 (ETS transcription factor) in OC chemoresistance is not well understood.
Purpose of the Study:
- To investigate the role and molecular mechanisms of ELK3 in OC cisplatin resistance.
- To explore the ELK3-CHD4-histone lactylation axis as a potential therapeutic target.
Main Methods:
- Analyzed ELK3 expression in OC cells and tissues (qPCR, Western blotting).
- Performed functional assays (CCK-8, apoptosis, xenografts) to assess ELK3 impact.
- Investigated mechanisms using Co-IP and histone lactylation analysis.
Main Results:
- ELK3 was upregulated in resistant OC tissues/cells, correlating with poor survival.
- ELK3 knockdown sensitized cells to cisplatin by reducing CHD4 and histone lactylation.
- Restoring CHD4 rescued cisplatin resistance in ELK3-deficient cells.
Conclusions:
- The ELK3-CHD4-histone lactylation axis is crucial for OC cisplatin resistance.
- This pathway represents a potential therapeutic target for overcoming chemoresistance in ovarian cancer.
Related Concept Videos
Abnormal Proliferation
Treatment Resistant Cancers
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
